Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1786-1793

  Nakai, Kenya ^a,b   Tanaka, Hiromasa ^a,b   Hanada, Kazuhiko ^b   Ogata, Hiroyasu ^b   Suzuki, Fumitaka ^c   Kumada, Hiromitsu ^c   Miyajima, Atsuko ^a   Ishida, Seiichi ^a   Sunouchi, Momoko ^a   Habano, Wataru ^d   Kamikawa, Yuichiro ^e   Kubota, Keiichi ^e   Kita, Junji ^e   Ozawa, Shogo ^a,d   Ohno, Yasuo ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ATENOLOL; BROTIZOLAM; CARRIER PROTEIN; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLIMEPIRIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCYRRHIZIC ACID; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NATEGLINIDE; NICARDIPINE; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; RNA; SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; TRIAZOLAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ARTICLE; CELL STRAIN HEPG2; CHRONIC HEPATITIS; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; RNA EXTRACTION;

CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; ISOENZYMES; LIVER CIRRHOSIS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYMPORTERS;

HEPATITIS C VIRUS;

EID: 50049122662     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.020073     Document Type: Article

References (35)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier J-C, Corcos L, Turlin B, Beaune P, and Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715.
2. Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M, et al. (2005) Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129:2064-2075.
3. Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre J-M, Maurel P, Vilarem MJ, and Pascussi JM (2004) Interleukin 1b inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 40:951-960.
4. Bièche I, Asselah T, Laurendau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla D-C, Marcellin P, and Vidaud M (2005) Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 332:130-144.
5. Caro AA and Cederbaum AI (2004) Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44:27-42.
6. Choi J, Lee KJ, Zheng Y, Yamada AK, Lai MMC, and Ou J-h (2004) Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39:81-89.
7. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
8. Crawford JH, Yang S, Zhou M, Simms HH, and Wang P (2004) Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med 32:502-508.
9. Desmet VJ, Gerber M, Hoofnagale JH, Manns M, and Sheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513-1520.
10. Dey A, Kessova IG, and Cederbaum AI (2006) Decreased protein and mRNA expression of ER stress proteins GRP78 and GRP94 in HepG2 cells over-expressing CYP2E1. Arch Biochem Biophys 447:155-166.
11. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, et al. (2005) Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128:334-342.
12. Fukuda Y, Ishida N, Noguchi T, Kappas A, and Sassa S (1992) Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochem Biophys Res Commun 184:960-965.
13. Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, and Powell EE (2003) Steatosis in chronic hepatitis C: association with increased RNA expression of collagen I, tumor necrosis factor-a and cytochrome P4502E1. J Gastroenterol Hepatol 18:386-392.
14. Grønbaek K, Sonne J, Ring-Larsen H, Poulsen HE, Friis H, and Krarup HB (2005) Viral load is a negative predictor of antioxidant levels in hepatitis C patients. Scand J Infect Dis 37:686-689
15. Hakkola J, Hu Y, and Ingelman-Sundberg M (2003) Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther 304:1048-1055.
16. Hayashi S, Yasui H, and Sakurai H (2005) Essential role of singlet oxygen species in cytochrome P450-dependent substrate oxygenation by rat liver microsomes. Drug Metab Pharmacokinet 20:14-23.
17. Horiike N, Abe M, Kumagai T, Hiasa Y, Akbar SMF, Michitaka K, and Onji M (2005) The quantification of cytochrome P-450 (CYP3A4) mRNA in the blood of patients with viral liver diseases. Clin Biochem 38:531-534.
18. Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, and Morgan ET (1999) Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev 31:29-41.
19. Ito T, Asakura K, Tougou K, Fukuda T, Kubota R, Nonen S, Fujio Y, and Azuma J (2007) Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes. Mol Pharmacol 72:173-181.
20. Jover R, Bort R, Gomez-Lechon MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved. FASEB J 16:1799-1801.
21. Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, and Kullak-Ublick GA (2001) Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1a. J Biol Chem 276:37206-37214.
22. Kessova I and Cederbaum AI (2003) CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 3:509-518.
23. Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, Balasubramaniyan N, Suchy FJ, Matern S, and Gartung C (2005) Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 289:G831-G841.
24. Le Vee M, Gripon P, Stieger B, and Fardel O (2008) Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1β. Drug Metab Dispos 36:217-222.
25. Levent G, Ali A, Ahmet A, Polat EC, Aytac C, Ayse E, and Ahmet S (2006) Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 4:25-30.
26. Mahmoud M, Abdel-Kader R, Hassanein M, Saleh S, and Botros S (2007) Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients. Eur J Pharmacol 569:222-227.
27. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, and Sugiyama Y (2006) Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am J Physiol Gastrointest Liver Physiol 290:G550-G556.
28. Muntané-Relat J, Ourlin JC, Domergue J, and Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153.
29. Navasumrit P, Ward TH, Dodd NJF, O'Connor PJ (2000) Ethanol-induced free radicals and hepatic DNA strand breaks are prevented in vivo by antioxidants: effects of acute and chronic ethanol exposure. Carcinogenesis 21:93-99.
30. Otani K, Korenaga M, Beard MR, Li K, Qian T, Showalter LA, Singh AK, Wang T, and Weinman SA (2005) Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 128:96-107.
31. Rendic S (2002) Summary of information on human CYP enzymes: human cytochrome P450 metabolism data. Drug Metab Rev 34:83-448.
32. Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235-243.
33. Saborowski M, Kullak-Ublick GA, and Eloranta JJ (2006) The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4a. J Pharmacol Exp Ther 317:778-785.
34. Shertzer HG, Clay CD, Genter MB, Schneider SN, Nebert DW, and Dalton TP (2004) CYP1A2 protects against reactive oxygen production in mouse liver microsomes. Free Radic Biol Med 36:605-617.
35. Wen F, Abdalla MY, Aloman C, Xiang J, Ahmad IM, Walewski J, McCormick ML, Brown KE, Branch AD, Spitz DR, et al. (2004) Increased prooxidant production and enhanced susceptibility to glutathione depletion in HepG2 cells co-expressing HCV core protein and CYP2E1. J Med Virol 72:230-240.